Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma

Next Previous
X
Search
Trial Profile

A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fevipiprant (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Acronyms SPIRIT
  • Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals

    • Most Recent Events

    • 08 May 2020 Status changed from recruiting to discontinued.
    • 16 Apr 2020 This trial has been discontinued in Austria , according to European Clinical Trials Database record. (2020-03-16)
    • 15 Apr 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top